TARS 📈 Tarsus Pharmaceuticals - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US87650L1035
TARS: Eye Drops, Creams, Pills
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Web URL: https://www.tarsusrx.com
Additional Sources for TARS Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
TARS Stock Overview
| Market Cap in USD | 1,980m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2020-10-16 |
TARS Stock Ratings
| Growth 5y | 43.9% |
| Fundamental | 12.4% |
| Dividend | - |
| Rel. Strength Industry | 24769 |
| Analysts | 4.56/5 |
| Fair Price Momentum | 52.71 USD |
| Fair Price DCF | - |
TARS Dividends
No Dividends PaidTARS Growth Ratios
| Growth Correlation 3m | 97.2% |
| Growth Correlation 12m | 50.5% |
| Growth Correlation 5y | 3.5% |
| CAGR 5y | 26.47% |
| CAGR/Mean DD 5y | 0.54 |
| Sharpe Ratio 12m | 1.94 |
| Alpha | 151.84 |
| Beta | 0.93 |
| Volatility | 54.88% |
| Current Volume | 742k |
| Average Volume 20d | 516.6k |
What is the price of TARS stocks?
As of January 02, 2025, the stock is trading at USD 55.37 with a total of 742,027 shares traded.
Over the past week, the price has changed by +1.88%, over one month by +9.82%, over three months by +71.48% and over the past year by +174.65%.
As of January 02, 2025, the stock is trading at USD 55.37 with a total of 742,027 shares traded.
Over the past week, the price has changed by +1.88%, over one month by +9.82%, over three months by +71.48% and over the past year by +174.65%.
Is Tarsus Pharmaceuticals a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Tarsus Pharmaceuticals is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 12.38 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TARS as of January 2025 is 52.71. This means that TARS is currently overvalued and has a potential downside of -4.8%.
Neither. Based on ValueRay Fundamental Analyses, Tarsus Pharmaceuticals is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 12.38 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TARS as of January 2025 is 52.71. This means that TARS is currently overvalued and has a potential downside of -4.8%.
Is TARS a buy, sell or hold?
Tarsus Pharmaceuticals has received a consensus analysts rating of 4.56. Therefor, it is recommend to buy TARS.
Tarsus Pharmaceuticals has received a consensus analysts rating of 4.56. Therefor, it is recommend to buy TARS.
- Strong Buy: 6
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecast for TARS stock price target?
According to ValueRays Forecast Model, TARS Tarsus Pharmaceuticals will be worth about 58.5 in January 2026. The stock is currently trading at 55.37. This means that the stock has a potential upside of +5.67%.
According to ValueRays Forecast Model, TARS Tarsus Pharmaceuticals will be worth about 58.5 in January 2026. The stock is currently trading at 55.37. This means that the stock has a potential upside of +5.67%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 65.3 | 18% |
| Analysts Target Price | 46 | -16.9% |
| ValueRay Target Price | 58.5 | 5.7% |